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Background

Methods

The Hippo Pathway is a signaling pathway that regulates various Below is a flow chart outlining the general procedures used in this study to
essential biological processes including cellular proliferation, cell discover and verify the PROTACs most effective in degrading YAP1 proteins.
survival, differentiation, organ size, and tissue homeostasis. YAP1
is a transcriptional co-activator and downstream effector in the
Hippo pathway1.
If overexpressed, YAP1 can become a highly potent oncogene
that plays a major role tumorigenesis and metastasis in various
types of cancer. This gene is overexpressed in 10% of all cancers
and seen in many solid tumors either by genetic copy number
amplification or by unknown pathways.
YAP1 activation also leads to resistance to common cancer
therapies such as cytotoxic chemotherapy, molecular targeted
therapy and radiotherapy2. Thus, targeting YAP1 requires
nontraditional drug and cancer technology.
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Fig 6 A-D. Western Blot and ImageJ analysis for YAP1 independent cell lines.

With all drugs at 20nM, we saw a reduction in YAP1 protein in both YAP1
dependent and independent cell lines within 4 hours of treatment.
Fig 3. Study methodology

Results
Primary screening followed by secondary validation identified about 32 molecules with
potential reduction of GFP levels tagged to the YAP1 protein. Some hits were further
validated by YAP1 western blot which suggested that some of the identified
compounds degraded YAP1.

The proliferation assay with the OV5 cell line showed a decrease in
proliferation at high concentrations in the CIDD-0150877, CIDD-0162266,
and CIDD-0162288 compounds. There was no decrease in proliferation at any
concentration for compound CIDD-0162289.
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CIDD-015087, was identified as a lead compound in degrading YAP1. Through qSAR
of this compound three PROTACs, CIDD-0162266, CIDD-0162288, and CIDD0162289, were synthesized. The efficacy of these four compounds were measured in
YAP1 independent and YAP1 dependent cell lines after 4 hours of treatment.
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Fig 1. Hippo Signaling Pathway Mechanism
Han Y. Analysis of the role of the Hippo pathway in cancer. J Transl
Med. 2019 Apr 8;17(1):116

PROTACs are a novel drug technology that regulate protein
function by completely degrading the target protein rather than
inhibiting it. PROTACs are sensitive to drug resistant targets,
effective at low concentrations, can target undruggable targets,
and can influence nonenzymatic functions, making them unique
from other drug technologies4.
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Fig 4 A-B. Western Blot and ImageJ analysis for OV5.

Fig 7. A: Proliferation assay results for CIDD-0150877. B: Proliferation results for
PROTAC CIDD-0162266. C: Proliferation results for PRTOAC CIDD-0162288. D:
Proliferation results for PROTAC CIDD-0162289.
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In compounds CIDD-0150877, CIDD-0162266, and CIDD-0162288, the two
highest concentrations decreased the viability of the OV5 cells. OV5 cell line
proliferation is not dependent on the presence of YAP1, these high
concentrations may suggest toxicity to this cell line. The lack of any change at
any concentration in the CIDD-0162289 assay suggest that the compound
might not be effective.

Fig 2. PROTAC structure and mode of Action
Sun et al Nature. (2019) 4:64

Conclusion

Introduction

Our data show that these four novel molecules that can significantly reduce
YAP1 protein levels in different cell lines. This data suggests that these
compounds could be useful agents to target YAP1-dependent cancers and
could offer significant improvements in a short amount of time.

Since YAP1 plays an oncogenic role in many different cancers, it
is important to target this protein for cancer treatment, however,
it does not have any targetable enzymatic activity. This makes
novel blocking strategies, such as PROTAC’s, important for
possible treatment. Since YAP1 has been shown to be regulated
by proteasomal mediated degradation, we reasoned that it may
be possible to identify chemicals/PROTACS that promote YAP1
degradation. To achieve this, we performed a high-throughput
chemical screen to identify compounds/PROTACs that could
degrade YAP1 proteins. Followed by western blot verification.
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Fig 5 A-D. Western Blot and ImageJ analysis for YAP1 Dependent cell lines.

Future Direction
Our future steps include conducting proliferation assays using all the drugs
on YAP1 independent and dependent cell lines. After this we hope to
validate these results through in vivo studies.
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